{
    "clinical_study": {
        "@rank": "116090", 
        "acronym": "THILAO", 
        "arm_group": {
            "arm_group_label": "Adherence reinforcement before switch to 3rd-line ART", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Thilao is a multi-country, phase 2b, non-randomized study, in Burkina Faso, Cote d'Ivoire,\n      Mali and Senegal, West Africa.\n\n      HIV-1 adults with 2nd-line ART virologic failure (plasma HIV-1 RNA >1000 copies/ml) will be\n      recruited and followed in two phases:\n\n        -  First, a 12-week intentive adherence reinforcement phase, during which patients will\n           continue 2nd-line ART, be seen repeatidly for counseling and educational training on\n           adherence, and be offered the possibility of phone, SMS and home visit contacts with\n           social workers;\n\n        -  Second, a 48-week phase, during which:\n\n             -  Patients successfully resuppressed at the end of the first phase will continue\n                2nd-line ART and adherence reinforcement;\n\n             -  Patients with persitent virologic failure will switch to a darunavir/r +\n                raltegravir-based 3rd-line ART.\n\n      Genotype resistance tests will be performed retrospectively on frozen samples. The main\n      outcome will be the percentage of patients with plasma HIV-1 viral RNA <50 copies/ml at 64\n      weeks."
        }, 
        "brief_title": "Third Line Antiretroviral Threatment Optimization in Sub-Saharan Africa", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Main objective\n\n      To estimate, in sub-Saharan African HIV-1 infected adults who failed a NNRTI-base first-line\n      ART and then a PI-based second-line ART:\n\n        1. The efficacy (and associated factors) at 12 weeks of an intensive 3-months adherence\n           reinfrocement phase;\n\n        2. In patients who successfully resuppress at 12 weeks: The percentage of patients still\n           with continuing succesfull virologic supression on 2nd-line ART at 64 weeks (and\n           factors associated to success) ;\n\n        3. In patients with persistent failure at 12 weeks : The efficacy (and associated factors)\n           at 64 weeks of a darunavir/r + raltegravir-based 3rd-line regimen.\n\n      Number of participants : 200\n\n      Main outcome :\n\n        -  At 12 weeks : Proportion of patients with a plasma HIV-1 RNA <400 copies/ml and/or with\n           a decrease in plasma HIV-1 RNA >2 log10 copies/ml between inclusion and 12 weeks;\n\n        -  At 64 weeks : proportion of patients with a plasma HIV-1 RNA <50 copies/ml.\n\n      Inclusion criteria:\n\n        -  Age >18 years\n\n        -  Documented HIV-1 infection.\n\n        -  History of failing a NNRTI-based 1st-line ART\n\n        -  Current PI-based 2nd-line ART >6 months\n\n        -  Plasma HIV-1 RNA >1000 copies/ml\n\n        -  Signed informed consent"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >18 years\n\n          -  Documented HIV-1 infection\n\n          -  History of failing a NNRTI-based 1st-line ART\n\n          -  Current PI-based 2nd-line ART >6 months\n\n          -  Plasma HIV-1 RNA >1000 copies/ml\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  HIV-2 infection\n\n          -  Any Severe clinical event under exploration\n\n          -  History of treatment including darunavir or raltegravir."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02025868", 
            "org_study_id": "ANRS 12269 THILAO"
        }, 
        "intervention": [
            {
                "arm_group_label": "Adherence reinforcement before switch to 3rd-line ART", 
                "description": "Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.", 
                "intervention_name": "adherence reinforcement", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Adherence reinforcement before switch to 3rd-line ART", 
                "description": "Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.\nThird-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)", 
                "intervention_name": "Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Darunavir"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Africa", 
            "Antiretroviral Treatment", 
            "Adherence reinforcement", 
            "Third line ART", 
            "Second line ART", 
            "Virologic failure", 
            "Adults"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "link": [
            {
                "description": "Sponsor site", 
                "url": "http://anrs.fr/"
            }, 
            {
                "url": "http://www.mereva.net/"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "sawadogoadrien@yahoo.fr", 
                    "last_name": "Adrien B Sawadogo, MD", 
                    "phone": "+22620985255"
                }, 
                "contact_backup": {
                    "email": "zojacques@yahoo.fr", 
                    "last_name": "Jacques Zoungrana, MD", 
                    "phone": "+22672303821"
                }, 
                "facility": {
                    "address": {
                        "city": "Bobo-Dioulasso", 
                        "country": "Burkina Faso"
                    }, 
                    "name": "CHU Sour\u00f4 Sanou"
                }, 
                "investigator": {
                    "last_name": "Jacques Zoungrana, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "messou_eugene@yahoo.fr", 
                    "last_name": "Eug\u00e8ne Messou, MD, PhD", 
                    "phone": "+22523462551"
                }, 
                "contact_backup": {
                    "email": "amani_anzian@yahoo.fr", 
                    "last_name": "Ama Anzian, MD", 
                    "phone": "+22540185774"
                }, 
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire"
                    }, 
                    "name": "Centre de Prise en Charge et de Formation (CePReF), Association ACONDA"
                }, 
                "investigator": {
                    "last_name": "Amani Anzian, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bissagnene@yahoo.fr", 
                    "last_name": "Emmanuel Bissagnene, MD, Pr", 
                    "phone": "+22521755960"
                }, 
                "contact_backup": {
                    "email": "ellonogboufrdric@yahoo.fr", 
                    "last_name": "Fr\u00e9d\u00e9ric Ello, MD", 
                    "phone": "+22521755960"
                }, 
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire"
                    }, 
                    "name": "Service des Maladies Infectieuses et Tropicales (SMIT)"
                }, 
                "investigator": {
                    "last_name": "Eboumou Gole, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "douada_minta@yahoo.fr", 
                    "last_name": "Daouda K Minta, MD", 
                    "phone": "+22320229790"
                }, 
                "contact_backup": {
                    "email": "matraore_cmbko@yahoo.fr", 
                    "last_name": "Abdoulaye Traor\u00e9, MD", 
                    "phone": "+22320229790"
                }, 
                "facility": {
                    "address": {
                        "city": "Bamako", 
                        "country": "Mali"
                    }, 
                    "name": "CHU Point G"
                }, 
                "investigator": {
                    "last_name": "Mahamadou Fomba, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "madci@yahoo.fr", 
                    "last_name": "Mamadou Ciss\u00e9, MD", 
                    "phone": "+22320236477"
                }, 
                "contact_backup": {
                    "email": "fodie10@yahoo.fr", 
                    "last_name": "Fodi\u00e9 Diallo, MD", 
                    "phone": "+22366731815"
                }, 
                "facility": {
                    "address": {
                        "city": "Bamako", 
                        "country": "Mali"
                    }, 
                    "name": "Centre d'Ecoute, de Soins, d'Animation et de Conseils (CESAC)"
                }, 
                "investigator": {
                    "last_name": "Konate Tiefing, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "seydi_moussa@gmail.com", 
                    "last_name": "Moussa Seydi, MD, Pr", 
                    "phone": "+221338231327"
                }, 
                "contact_backup": {
                    "email": "mamadoubaila@yahoo.fr", 
                    "last_name": "Mouhamadou B Diallo, MD", 
                    "phone": "+221776511773"
                }, 
                "facility": {
                    "address": {
                        "city": "Dakar", 
                        "country": "Senegal"
                    }, 
                    "name": "CHU Fann"
                }, 
                "investigator": {
                    "last_name": "Nogaye Gaye", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Burkina Faso", 
                "C\u00f4te D'Ivoire", 
                "Mali", 
                "Senegal"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Systematic \"Adherence Intervention\" Phase Before Switching to 3rd-line ART in Patients With 2nd-line ART Virologic Failure in Sub-Saharan Africa : a Phase 2b Non-randomized Study.", 
        "overall_contact": {
            "email": "raoul.moh@pacci.ci", 
            "last_name": "Raoul Desmoryl Moh, MD, PHD", 
            "phone": "+225 07 82 83 79"
        }, 
        "overall_contact_backup": {
            "email": "aida.benalycherif@gmail.com", 
            "last_name": "A\u00efda Benalcherif", 
            "phone": "+33 (1) 40 25 63 65"
        }, 
        "overall_official": [
            {
                "affiliation": "Service des Maladies Infectieuses et Tropicales,  CHU de Treichville, Abidjan, C\u00f4te d'Ivoire", 
                "last_name": "Serge P. Eholie, MD, MSc, Pr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut de M\u00e9decine et d'Epid\u00e9miologie Appliqu\u00e9e - H\u00f4pital Bichat Claude Bernard, Paris, France", 
                "last_name": "Roland Landman, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inserm 897, University of Bordeaux, France", 
                "last_name": "Xavier Anglaret, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Infectious Diseases Department, University Hospital Saint Antoine, Paris, France", 
                "last_name": "Pierre-Marie Girard, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Burkina Faso: Minist\u00e8re de la sant\u00e9", 
                "Burkina Faso: Minist\u00e8re de la Recherche Scientifique et de l'Innovation", 
                "Burkina Faso: Comit\u00e9 d'Ethique pour la Recherche en Sant\u00e9", 
                "Cote d'Ivoire: Minist\u00e8re de la Sant\u00e9 et de la Lutte contre le SIDA", 
                "Cote d'Ivoire: Comit\u00e9 National d'Ethique et de la Recherche", 
                "Mali: Minist\u00e8re de la sant\u00e9", 
                "Mali: Comit\u00e9 d'Ethique de l'Institut National de Recherche en Sant\u00e9 Publique", 
                "Senegal: Ministere de la Sante et de l'Action Sociale", 
                "Senegal: Comit\u00e9 National d'Ethique pour la Recherche en Sant\u00e9"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Proportion of patients with plasma viral load <400 copies/ml at Week 12 and/or with a decrease in plasma viral load >2 log10 copies/ml between inclusion and Week 12", 
                "measure": "Virologic efficacy of the adherence reinforcement intervention", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Proportion of patients with plasma viral load <50 copies/ ml at Week 64 among those who stayed on 2nd-line ART at Week 16", 
                "measure": "Persistent virologic efficacy of the adherence reinforcement intervention", 
                "safety_issue": "No", 
                "time_frame": "Week 64"
            }, 
            {
                "description": "Proportion of patients with HIV-1 plasma viral load <50 copies/ml at Week 64 among those with persistent failure at Week 12 who switched to 3rd-line ART", 
                "measure": "Virologic efficacy of 3rd-line ART", 
                "safety_issue": "No", 
                "time_frame": "Week 64"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02025868"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "CD4 count evolution between inclusion and Week 12", 
                "measure": "Immunological efficacy of the adherence reinforcement intervention", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "CD4 count evolution between Week12 and Week 64 among patients who switched to 3rd-line ART at Week 16", 
                "measure": "Immunological efficacy of 3rd-line ART", 
                "safety_issue": "No", 
                "time_frame": "Week 64"
            }, 
            {
                "description": "Incidence of grade 3-4 adverse events (ANRS grading table) in patients on 3rd-line ART", 
                "measure": "Tolerance of 3rd-line ART drugs", 
                "safety_issue": "Yes", 
                "time_frame": "Week 64"
            }, 
            {
                "description": "3rd-line Medication Possession Ratio between Week 16 and Week 64", 
                "measure": "Adherence  to 3rd-line ART", 
                "safety_issue": "No", 
                "time_frame": "Week 64"
            }, 
            {
                "description": "Resistance mutations to antiretroviral drugs among patients with virological failure at Week 12", 
                "measure": "Resistance to 1st and 2nd-line antiretroviral drugs", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Resistance mutations to antiretroviral drugs among patients with virological failure at Week 64", 
                "measure": "Resistance to 1st, 2nd and 3rd-line antiretroviral drugs", 
                "safety_issue": "No", 
                "time_frame": "Week 64"
            }, 
            {
                "description": "Plasma antiretroviral drugs concentration at Week 12", 
                "measure": "Plasma antiretroviral drugs concentration", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Plasma antiretroviral drugs concentration at Week 64", 
                "measure": "Plasma antiretroviral drugs concentration", 
                "safety_issue": "No", 
                "time_frame": "Week 64"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}